About the Company
The Burzynski Clinic is a clinic selling an unproven cancer treatment, which has been characterized as harmful quackery. It was founded in 1976 and is located in Houston, Texas, in the United States. It offers a form of chemotherapy originally called "antineoplaston therapy" devised by the clinic's founder Stanislaw Burzynski in the 1970s. Antineoplaston is Burzynski's term for a group of urine-derived peptides, peptide derivatives, and mixtures. There is no accepted scientific evidence of benefit from antineoplaston combinations for various diseases, and the Clinic's claimed successes have not been replicated by independent researchers. The therapy has been rebranded in various ways over the years to mirror fashions in medicine, for example as a kind of "immunotherapy". The therapy is administered through the ruse of running a large numbers of clinical trials, which long-time Burzynski lawyer Richard Jaffe has described as "a joke". The clinic has been the focus of criticism primarily due to the way its antineoplaston therapy is promoted, the costs for people with cancer participating in trials of antineoplastons and problems with the way these trials are run. Legal cases have been brought as a result of the sale of the therapy without regulatory approval. Burzynski is also the president and founder of a pharmaceutical company, the Burzynski Research Institute, which manufactures his antineoplaston drugs.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on BURZYNSKI RESEARCH INSTITUTE INC
Burzynski Research Institute Inc BZYR - Morningstar
Review Burzynski Research Institute Inc (BZYR:PINX) stock and the current sustainability and ESG risk rating to help with your investing decisions.
BZYR | Burzynski Research Institute Inc. Financial Statements - WSJ
Burzynski Research Institute Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View BZYR financial statements in full.
Burzynski Research Institute Inc. (BZYR) SEC Filings | Nasdaq
Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...
Burzynski Research Institute Inc. (BZYR) Pre-Market Quotes
Burzynski Research Institute Inc. (BZYR) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.
Burzynski Research Short Interest Report - Benzinga
Short interest in Burzynski Research Institute Inc (OTC:BZYR) decreased during the last reporting period, falling from 16.56K to 5.56K. This put 0.02% of the company's publicly available shares short.
Burzynski Research Institute Inc. BZYR (U.S.: OTC) - The Wall Street ...
Burzynski Research Institute Inc. BZYR (U.S.: OTC) View All companies AT CLOSE 1:09 PM EDT 06/16/25 $0.037 USD Volume 11,000 ...
Press Release | Burzynski Research Institute Inc - Stockhouse
Burzynski Research Institute, Inc. (BRI) announced today that it has begun patient enrollment into an FDA-reviewed and IRB-approved, open-label, single-arm phase 2 study of Antineoplastons A10 and AS2 ...
Burzynski Research Institute Partners with Premier Research to Manage ...
Media: Burzynski Research Institute, Inc. Darlene Hodge, 713-335-5636 Darlene@burzynskiclinic.com or Carolyn Powers, 713-335-5664 Carolyn@burzynskiclinic.com or Amanda Cheslock, 212-446-1884 ...
Burzynski Research Institute, Inc. (BZYR) - Yahoo Finance
Find the latest Burzynski Research Institute, Inc. (BZYR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Burzynski Research Institute, Inc. Announces the Launch of a New ...
Burzynski Research Institute, Inc. (OTCBB:BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles.
Burzynski Research Institute Inc BZYR - Morningstar
Review quarterly and annual revenue, net income, and cash flow for Burzynski Research Institute Inc (BZYR:PINX) stock through the last fiscal year.
Similar Companies
Loading the latest forecasts...